GLP-1 receptor agonists show potential benefits for metabolic dysfunction-associated steatotic liver disease with acceptable safety

This umbrella review examined the efficacy and safety of GLP-1 receptor agonists in patients with metabolic dysfunction-associated steatotic liver disease. The analysis included twenty-three meta-analyses and systematic reviews that assessed liver characteristics, enzyme levels, and metabolic markers. The authors observed potential benefits in improving the disease across multiple dimensions with a relatively acceptable safety profile. Serious adverse events and discontinuations were not reported in the included literature.

Despite these positive observations, the authors highlight significant limitations within the evidence base. Nearly eighty percent of the included reviews were assessed as having critically low quality. Furthermore, there was high evidence overlap among the studies, which limits the ability to draw definitive conclusions. The authors explicitly state that these findings are preliminary and hypothesis-generating rather than conclusive.

Given the current state of the literature, the authors emphasize that high-quality studies are urgently needed to confirm these observations. Until such robust data becomes available, clinicians should interpret these results with caution. The review serves as a starting point for understanding potential therapeutic roles but does not yet support definitive clinical recommendations.